title: Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice.
abstract: Rotavirus virus-like particles (RV-VLPs) represent a novel strategy for development of a rotavirus subunit vaccine. In this study, RF 8-2/6/7-VLPs with rotavirus VP8 protein (amino acid 1-241 of VP4) fused to the amino terminal end of a truncated VP2, were evaluated for their immunogenic and protective properties. A single intramuscular dose of, either 2 or 20 microg, RF 8-2/6/7-VLPs alone or combined with a potent adjuvant poly[di(carboxylatophenoxy)]phosphazene] (PCPP) induced rotavirus-specific serum IgG and IgA, fecal IgG titers that were enhanced 5-90-fold by adjuvant. Passive protective immunity was achieved in offspring to dams vaccinated with 2 and 20 microg RV-VLPs in presence of adjuvant and 20 microg RV-VLP without adjuvant.
authors.affiliation: Instituto de Biologia Experimental e Tecnologica and Instituto de Tecnologia Quimica e Biologica, SE-171 76 Oeiras, Portugal.
authors.forename: Claudia
authors.initials: C
authors.lastname: Istrate
authors.forename: Jorma
authors.initials: J
authors.lastname: Hinkula
authors.forename: Annie
authors.initials: A
authors.lastname: Charpilienne
authors.forename: Didier
authors.initials: D
authors.lastname: Poncet
authors.forename: Jean
authors.initials: J
authors.lastname: Cohen
authors.forename: Lennart
authors.initials: L
authors.lastname: Svensson
authors.forename: Kari
authors.initials: K
authors.lastname: Johansen
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005243:Feces / Q000737:chemistry; D005260:Female; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood; D007273:Injections, Intramuscular; D051379:Mice; D008807:Mice, Inbred BALB C; D046529:Microscopy, Electron, Transmission; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000276:immunology; D011108:Polymers / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D012401:Rotavirus / Q000276:immunology*; D012400:Rotavirus Infections / Q000517:prevention & control*; D022721:Vaccines, Virosome / Q000008:administration & dosage / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D022701:Virosomes / Q000648:ultrastructure
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; C070410:Ca-poly(bis(carboxylatophenoxy)phosphazene); D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009943:Organophosphorus Compounds; D011108:Polymers; D011993:Recombinant Fusion Proteins; D022721:Vaccines, Virosome; D014764:Viral Proteins; D022701:Virosomes